Compare iShares China Large-Cap ETF (FXI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Tempus AI — how do they compare? iShares China Large-Cap ETF trades at $33.9 (market cap $3.90B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Tempus AI is far larger — about 3.3× iShares China Large-Cap ETF's market cap, and Tempus AI is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Tempus AI for 22 Days on average.
| FXI | TEM | |
|---|---|---|
Market Cap | $3.90B | $12.77B |
Volume | 16,526,479 | 8,980,490 |
52-Week High | $41.08 | $99.28 |
52-Week Low | $31.59 | $41.55 |
Typical Hold Time | 149 Days | 22 Days |
Sector | — | Broad Market / Factor |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $33.42, down 1.04% with a bearish technical outlook. The ETF shows compelling valuation at half the S&P 500's P/E ratio with a 1.98% yield, but faces headwinds from China's economic challenges and geopolitical tensions. Recent corporate profit growth of 26% in Q2 2026 provides fundamental support, though weak momentum persists amid global trade concerns.
The ETF offers diversification value and valuation appeal but carries significant political and economic risks. China's industrial overcapacity and weak domestic consumption create volatility, while U.S.-China relations remain a key variable. Institutional interest focuses on long-term value despite near-term bearish technical signals.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
